Kodiak Sciences shares surge after eye drug succeeds in late-stage study

Shares of drug developer Kodiak Sciences jumped 52% before the bell on Thursday after its experimental ​drug met the main goal in a ‌late-stage study in patients with diabetes-related eye damage.